The Indian Pharmaceutical Market (IPM) registered an 8.1 per cent year-on-year growth in August 2025. This comes after a 7.1 per cent growth in July and aligns closely with the overall 8 per cent growth seen in FY25. Citing data by IQVIA, HDFC Securities Pharmaceuticals report noted that uni
New Delhi [India], September 19: PharmaHopers has levelled up its B2B pharma portal and made it easier for clients to connect with India's top pharma companies. Once required, time-consuming searches and multiple touches have been transformed into just one click away. It brings India's top p
Ahmedabad (Gujarat) [India], September 18: In India's complex and expensive healthcare ecosystem, where sufferers still consume a significant portion of their income on pharmaceuticals, a quiet transformation is ongoing. While digital health startups often lead headlines, one drugstore chain
India's pharmaceutical industry is set to record healthy revenue growth of 7-9 per cent in FY26, even as challenges in the United States market continue to weigh on performance, noted rating agency ICRA in its latest sector outlook.
The Indian Pharmacopoeia Commission (IPC), functioning as the National Coordination Centre for the Pharmacovigilance Programme of India (NCC-PvPI), inaugurated the 5th National Pharmacovigilance Week (NPW) at the Bharat Mandapam Convention Centre, New Delhi, a press release from the Ministry
The Indian pharmaceutical industry requires price increases, site and intellectual property (IP) transfers to deal with the prevailing uncertainty in the sector amid US tariffs, according to a report by Systematix Research
Raichur (Karnataka) [India], August 14: In a landmark moment for global hepatology and Indian pharmaceutical innovation, Shilpa Medicare Limited (BSE: 530661) (NSE: SHILPAMED) has secured the world's first regulatory approval from India's Central Drugs Standard Control Organization (CDSCO) f
Imposing tariffs on the pharmaceutical Industry will significantly impact the earnings of Indian pharma companies, as nearly 40 per cent of India's total pharma exports are directed to the US market
Indian pharmaceutical manufacturers are preparing a two-pronged strategy to offset the impact of the soon-to-be-effective 25 per cent US tariff on Indian goods, which includes drug exports, with industry experts anticipating that the move could significantly raise medicine costs in the Ameri
The Indian pharmaceutical industry has hit back strongly at the recent tariff announcement by U.S. President Donald Trump, calling it a move that could hurt the American healthcare system more than India's economy.
Indian pharma and healthcare sector will witness steady revenue growth in the first quarter of the Financial Year 2026 (Q1FY26E), but concerns loom as EBITDA margins are expected to decline amid rising input costs and pricing pressures, according to a report by HDFC Securities.